Development of Novel Antivirals against Flaviviruses

  1. Gregory Bock Organizer and
  2. Jamie Goode
  1. Chinmay G. Patkar and
  2. Richard J. Kuhn

Published Online: 7 OCT 2008

DOI: 10.1002/0470058005.ch4

New Treatment Strategies for Dengue and Other Flaviviral Diseases: Novartis Foundation Symposium 277

New Treatment Strategies for Dengue and Other Flaviviral Diseases: Novartis Foundation Symposium 277

How to Cite

Patkar, C. G. and Kuhn, R. J. (2008) Development of Novel Antivirals against Flaviviruses, in New Treatment Strategies for Dengue and Other Flaviviral Diseases: Novartis Foundation Symposium 277 (eds G. Bock and J. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470058005.ch4

Author Information

  1. Department of Biological Sciences, Purdue University, 915 West State St, West Lafayette, IN 47907-2054, USA

  1. This paper was presented at the symposium by Richard J. Kuhn, to whom correspondence should be addressed.

Publication History

  1. Published Online: 7 OCT 2008
  2. Published Print: 25 AUG 2006

Book Series:

  1. Novartis Foundation Symposia

Book Series Editors:

  1. Novartis Foundation

ISBN Information

Print ISBN: 9780470016435

Online ISBN: 9780470058008

SEARCH

Keywords:

  • dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS);
  • structure-based drug design and informative biochemical assays;
  • flavivirus replicon system construction;
  • flavivirus antivirals;
  • flavivirus E protein

Summary

Dengue virus is responsible for a significant amount of human disease in predominantly tropical areas of the world. Much effort has focused on the development of vaccines against the four serotypes of dengue, and within the next few years a vaccine is anticipated. Less progress has been made at developing antivirals that might reduce disease severity. Recent advances in the structural biology of dengue virus and other flaviviruses have opened new possibilities for the rational design of small molecule inhibitors of virus replication. This chapter describes the structural attributes of the dengue virion and how knowledge of its structure, assembly, and entry mechanisms are guiding new strategies toward the development of compounds that will interfere with the viral replication process.